BioCryst Pharmaceuticals, Inc. (BCRX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $8.44 (-1.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 5, 2025 | Jonathan Wolleben | JMP Securities | $25.00 | +196.4% |
| Oct 14, 2025 | Maury Raycroft | Jefferies | $15.00 | +77.8% |
| Aug 6, 2024 | Gena Wang | Barclays | $7.00 | -17.0% |
| Aug 5, 2024 | Maury Raycroft | Jefferies | $11.00 | +30.4% |
| Nov 2, 2022 | Liisa Bayko | Evercore ISI | $16.00 | +89.7% |
| Aug 23, 2022 | Gena Wang | Barclays | $14.00 | +66.0% |
| Jan 10, 2022 | Ken Cacciatore | Cowen & Co. | $25.00 | +196.4% |
| Nov 3, 2021 | Brian Cheng | Cantor Fitzgerald | $21.00 | +149.0% |
| Aug 9, 2021 | Maury Raycroft | Jefferies | $19.00 | +125.3% |
Top Analysts Covering BCRX
BCRX vs Sector & Market
| Metric | BCRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.18 | 2.25 | 2.41 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +125.3% | +153002.0% | +21.5% |
| P/E Ratio | 7.04 | 3.46 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $167M | $169M | $171M | 2 |
| 2027-03-31 | $168M | $170M | $172M | 2 |
| 2027-06-30 | $185M | $187M | $190M | 2 |
| 2027-09-30 | $191M | $193M | $195M | 2 |
| 2027-12-31 | $192M | $194M | $197M | 2 |
| 2028-12-31 | $862M | $875M | $887M | 6 |
| 2029-12-31 | $1.04B | $1.08B | $1.12B | 5 |
| 2030-12-31 | $1.25B | $1.30B | $1.35B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.07 | $0.07 | $0.07 | 1 |
| 2027-03-31 | $0.08 | $0.08 | $0.08 | 1 |
| 2027-06-30 | $0.12 | $0.12 | $0.12 | 1 |
| 2027-09-30 | $0.13 | $0.13 | $0.13 | 1 |
| 2027-12-31 | $0.15 | $0.15 | $0.15 | 1 |
| 2028-12-31 | $0.15 | $0.46 | $0.68 | 4 |
| 2029-12-31 | $0.97 | $1.02 | $1.07 | 2 |
| 2030-12-31 | $1.56 | $1.63 | $1.72 | 2 |
Frequently Asked Questions
What is the analyst consensus for BCRX?
The consensus among 11 analysts covering BioCryst Pharmaceuticals, Inc. (BCRX) is Buy with an average price target of $19.00.
What is the highest price target for BCRX?
The highest price target for BCRX is $25.00, set by Jonathan Wolleben at JMP Securities on 2025-11-05.
What is the lowest price target for BCRX?
The lowest price target for BCRX is $7.00, set by Gena Wang at Barclays on 2024-08-06.
How many analysts cover BCRX?
11 analysts have issued ratings for BioCryst Pharmaceuticals, Inc. in the past 12 months.
Is BCRX a buy or sell right now?
Based on 11 analyst ratings, BCRX has a consensus rating of Buy (2.18/5) with a +125.3% upside to the consensus target of $19.00.
What are the earnings estimates for BCRX?
Analysts estimate BCRX will report EPS of $0.07 for the period ending 2026-12-31, with revenue estimated at $169M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.